EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Prognostic Value of Gleason Score for Overall Survival in Prostate Cancer: A Population-Based SEER Cohort Study

Onyekachi Anya, Ogbonna Chikere, Progress Asoluka, Oluchi Idenyi, Alexandra O. Sokolova

Onco · 19.08.2026 · 6 (3) · 43

DOI: 10.3390/onco6030043 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Onco, online erschienen am 19.08.2026. Verfasst von Onyekachi Anya und 4 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Prostate cancer is biologically heterogeneous, and prognostic stratification informs the choice between definitive treatment and conservative management. Most evidence on the Gleason score addresses prostate cancer-specific mortality rather than survival from any cause. We assessed the association between Gleason score category and overall survival in a contemporary population-based cohort.

Methods

Using Surveillance, Epidemiology, and End Results (SEER) Research Data from 17 registries (November 2024 submission), we included men aged 40 years and older with a first primary malignant prostate cancer and a recorded Gleason Score Clinical Recode (2010+). Because this recode is undefined before 2010, the analytic period was 2010–2019. Gleason score was categorized as ≤6, 7, and ≥8. Overall survival was estimated by Kaplan–Meier methods and compared by log-rank test; multivariable Cox regression adjusted for age, race and ethnicity, marital status, summary stage, surgery at the primary site, radiation therapy, and chemotherapy, with localized disease as the stage reference.

Results

Among 374,763 men, 145,668 (38.9%) had Gleason ≤ 6, 148,773 (39.7%) Gleason 7, and 80,322 (21.4%) Gleason ≥ 8, with mortality during follow-up of 11.3%, 14.6% and 36.6% respectively (log-rank p < 0.0001). Adjusted hazards of death were higher for Gleason 7 (HR 1.53, 95% CI 1.50–1.57) and Gleason ≥ 8 (HR 2.89, 95% CI 2.82–2.95) relative to Gleason ≤ 6. Advancing age, regional disease (HR 1.47, 95% CI 1.43–1.51) and distant disease (HR 3.74, 95% CI 3.65–3.84) were also associated with increased mortality. The grade association attenuated over follow-up, the hazard ratio for Gleason ≥ 8 falling from 4.12 within two years to 2.17 beyond five years.

Conclusions

Gleason score category is independently associated with overall survival and retains prognostic value on the all-cause mortality scale, with greatest discrimination in the years immediately following diagnosis.

Zitieren

APA

Anya, O., Chikere, O., Asoluka, P., Idenyi, O., & Sokolova, A. O. (2026). Prognostic Value of Gleason Score for Overall Survival in Prostate Cancer: A Population-Based SEER Cohort Study. Onco, 6(3), 43. https://doi.org/10.3390/onco6030043

Vancouver

Anya O, Chikere O, Asoluka P, Idenyi O, Sokolova AO. Prognostic Value of Gleason Score for Overall Survival in Prostate Cancer: A Population-Based SEER Cohort Study. Onco. 2026;6(3):43. doi:10.3390/onco6030043

BibTeX
@article{Anya2026,
  author = {Anya, Onyekachi and Chikere, Ogbonna and Asoluka, Progress and Idenyi, Oluchi and Sokolova, Alexandra O.},
  title = {Prognostic Value of Gleason Score for Overall Survival in Prostate Cancer: A Population-Based SEER Cohort Study},
  journal = {Onco},
  year = {2026},
  volume = {6},
  number = {3},
  pages = {43},
  doi = {10.3390/onco6030043}
}
Kostenlos starten →